CA2903229A1 - Manufacture of peanut formulations for oral desensitization - Google Patents

Manufacture of peanut formulations for oral desensitization Download PDF

Info

Publication number
CA2903229A1
CA2903229A1 CA2903229A CA2903229A CA2903229A1 CA 2903229 A1 CA2903229 A1 CA 2903229A1 CA 2903229 A CA2903229 A CA 2903229A CA 2903229 A CA2903229 A CA 2903229A CA 2903229 A1 CA2903229 A1 CA 2903229A1
Authority
CA
Canada
Prior art keywords
ara
peanut
glidant
capsule
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2903229A
Other languages
English (en)
French (fr)
Inventor
Bryan Walser
Howard V. Raff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Aimmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2903229(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aimmune Therapeutics Inc filed Critical Aimmune Therapeutics Inc
Publication of CA2903229A1 publication Critical patent/CA2903229A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medical Informatics (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CA2903229A 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization Pending CA2903229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784964P 2013-03-14 2013-03-14
US61/784,964 2013-03-14
PCT/US2014/024401 WO2014159607A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Publications (1)

Publication Number Publication Date
CA2903229A1 true CA2903229A1 (en) 2014-10-02

Family

ID=51528061

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903229A Pending CA2903229A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Country Status (19)

Country Link
US (5) US9198869B2 (cg-RX-API-DMAC10.html)
EP (3) EP3482771B1 (cg-RX-API-DMAC10.html)
JP (3) JP6752140B2 (cg-RX-API-DMAC10.html)
CN (2) CN109125283A (cg-RX-API-DMAC10.html)
AU (5) AU2014240404B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015021756B1 (cg-RX-API-DMAC10.html)
CA (1) CA2903229A1 (cg-RX-API-DMAC10.html)
DK (2) DK2968529T3 (cg-RX-API-DMAC10.html)
ES (2) ES2826224T3 (cg-RX-API-DMAC10.html)
FI (2) FI3482771T3 (cg-RX-API-DMAC10.html)
FR (1) FR23C1026I2 (cg-RX-API-DMAC10.html)
HU (1) HUE051831T2 (cg-RX-API-DMAC10.html)
MX (1) MX2015010315A (cg-RX-API-DMAC10.html)
NL (1) NL301236I2 (cg-RX-API-DMAC10.html)
NO (1) NO2023027I1 (cg-RX-API-DMAC10.html)
PL (1) PL2968529T3 (cg-RX-API-DMAC10.html)
PT (1) PT2968529T (cg-RX-API-DMAC10.html)
SI (1) SI2968529T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014159607A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
JP6910946B2 (ja) 2014-08-25 2021-07-28 アイミューン セラピューティクス,インコーポレイテッド タマゴのタンパク質製剤およびその製造方法
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
WO2016134291A2 (en) 2015-02-20 2016-08-25 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂a及過敏原調配物
US10856567B2 (en) 2016-07-22 2020-12-08 Kari Brown Baby food products containing allergenic proteins and methods of delivering same
PT3548079T (pt) * 2016-12-05 2023-07-27 Reacta Biotech Ltd Formulações de refeições para provocação oral
CN110381749A (zh) * 2017-01-13 2019-10-25 艾慕恩治疗公司 坚果粉的制造方法和用于口服免疫疗法的配方
AU2017279647B2 (en) 2017-02-15 2022-05-26 Euroimmun Medizinische Labordiagnostika Ag An improved assay for the diagnosis of peanut allergy
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
US11369676B2 (en) 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy
GB201718342D0 (en) * 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
EP3740223A4 (en) 2018-01-16 2021-10-20 Tel HaShomer Medical Research Infrastructure and Services Ltd. TREATMENT AND PREVENTION OF SEED ALLERGIES
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) * 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CA3123605A1 (en) * 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
US11766477B2 (en) 2019-01-23 2023-09-26 Societe Des Produits Nestle S.A. Methods for making mixed allergen compositions
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
ES3038192T3 (en) * 2019-08-08 2025-10-10 Evonik Operations Gmbh Method of preparing a solid dosage form and a lubricant
WO2021102186A1 (en) * 2019-11-20 2021-05-27 Aimmune Therapeutics, Inc. Methods and systems for managing distribution and treatment of a food allergy oral immunotherapy drug
AU2020410909A1 (en) * 2019-12-23 2022-07-14 Prota Therapeutics Pty Ltd Pharmaceutical compositions
JP7756664B2 (ja) 2020-07-01 2025-10-20 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 経口免疫療法のための医療スタッフ配置の決定
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
US20250325658A1 (en) 2022-04-11 2025-10-23 Alk-Abelló A/S Peanut allergen compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) * 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) * 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
US20020018778A1 (en) 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
EP1272213B1 (en) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
CA2516291C (en) 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
EP2545931A1 (en) 2004-03-19 2013-01-16 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
WO2007075171A1 (en) 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
FR2924349B1 (fr) * 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
CN102215825A (zh) 2008-11-19 2011-10-12 安万托特性材料股份有限公司 可直接压制的颗粒状的基于微晶纤维素的赋形剂、其制备方法及应用
WO2010069595A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
CN101912364B (zh) * 2010-08-09 2015-07-15 刘会梅 银杏内酯b脂质体组合药物
GB201104537D0 (en) * 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
EP2750705B1 (en) * 2011-08-31 2022-11-16 Perosphere Technologies Inc. Methods for effectively and rapidly desensitizing allergic patients
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
JP6910946B2 (ja) 2014-08-25 2021-07-28 アイミューン セラピューティクス,インコーポレイテッド タマゴのタンパク質製剤およびその製造方法
CN110381749A (zh) 2017-01-13 2019-10-25 艾慕恩治疗公司 坚果粉的制造方法和用于口服免疫疗法的配方
US11369676B2 (en) 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy

Also Published As

Publication number Publication date
US11141352B2 (en) 2021-10-12
US20160030289A1 (en) 2016-02-04
FI3482771T3 (fi) 2023-04-03
FR23C1026I1 (fr) 2023-10-06
JP2016512537A (ja) 2016-04-28
JP2021073321A (ja) 2021-05-13
SI2968529T1 (sl) 2021-03-31
BR112015021756A2 (pt) 2017-07-18
AU2020202685A1 (en) 2020-05-14
EP3482771B1 (en) 2023-01-18
NO2023027I1 (no) 2023-07-06
AU2018222980A1 (en) 2018-09-20
ES2940686T3 (es) 2023-05-10
US20200129378A1 (en) 2020-04-30
US10449118B2 (en) 2019-10-22
BR112015021756A8 (pt) 2019-11-19
DK3482771T3 (da) 2023-03-20
MX2015010315A (es) 2016-04-13
DK2968529T3 (da) 2020-10-12
WO2014159607A1 (en) 2014-10-02
CN105101994B (zh) 2018-10-12
FR23C1026I2 (fr) 2024-07-26
EP2968529A1 (en) 2016-01-20
PT2968529T (pt) 2020-11-10
BR112015021756B1 (pt) 2023-01-10
ES2826224T3 (es) 2021-05-17
NL301236I2 (nl) 2025-07-31
US20180042816A1 (en) 2018-02-15
EP3482771A1 (en) 2019-05-15
AU2020202685B2 (en) 2022-01-20
HK1217660A1 (zh) 2017-01-20
EP2968529B1 (en) 2020-08-05
US9198869B2 (en) 2015-12-01
US20140271836A1 (en) 2014-09-18
PL2968529T3 (pl) 2021-04-19
EP3998080A1 (en) 2022-05-18
AU2016231523B2 (en) 2018-05-31
US20230120350A1 (en) 2023-04-20
CN109125283A (zh) 2019-01-04
AU2014240404A1 (en) 2015-09-17
JP6752140B2 (ja) 2020-09-09
AU2022201858B2 (en) 2024-04-04
FIC20230022I1 (fi) 2023-07-04
EP2968529A4 (en) 2016-10-05
AU2022201858A1 (en) 2022-04-07
AU2016231523A1 (en) 2016-10-06
JP7454519B2 (ja) 2024-03-22
CN105101994A (zh) 2015-11-25
AU2014240404B2 (en) 2016-07-21
JP6891205B2 (ja) 2021-06-18
HUE051831T2 (hu) 2021-03-29
JP2019108357A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
AU2022201858B2 (en) Manufacture of peanut formulations for oral desensitization
US20230139230A1 (en) Egg protein formulations and methods of manufacture thereof
EP3568027A1 (en) Methods of manufacture of nut flours and formulations for oral immunotherapy
HK40008413A (en) Manufacture of peanut formulations for oral desensitization
HK40008413B (en) Manufacture of peanut formulations for oral desensitization
HK40003142A (en) Manufacture of peanut formulations for oral desensitization
HK1217660B (en) Manufacture of peanut formulations for oral desensitization

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250207

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250403

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250514

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260504

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260528

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260528